KemPharm Inc (NASDAQ:KMPH) – Stock analysts at Oppenheimer Holdings cut their Q2 2017 earnings estimates for shares of KemPharm in a report released on Wednesday. Oppenheimer Holdings analyst D. Archila now forecasts that the specialty pharmaceutical company will post earnings of ($0.63) per share for the quarter, down from their previous forecast of ($0.61). Oppenheimer Holdings currently has a “Buy” rating and a $13.00 target price on the stock. Oppenheimer Holdings also issued estimates for KemPharm’s Q3 2017 earnings at ($0.66) EPS, FY2017 earnings at ($2.81) EPS, FY2019 earnings at ($0.57) EPS and FY2020 earnings at $0.17 EPS.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.21.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/05/15/q2-2017-eps-estimates-for-kempharm-inc-reduced-by-oppenheimer-holdings-kmph.html.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity set a $7.00 price target on shares of KemPharm and gave the company a “buy” rating in a research note on Sunday, March 12th. Zacks Investment Research lowered shares of KemPharm from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. Finally, Royal Bank of Canada set a $8.00 price target on shares of KemPharm and gave the company a “buy” rating in a research note on Wednesday, April 12th.

Shares of KemPharm (NASDAQ:KMPH) opened at 4.20 on Monday. The company has a 50-day moving average price of $4.42 and a 200 day moving average price of $3.89. The company’s market capitalization is $61.51 million. KemPharm has a one year low of $2.90 and a one year high of $7.84.

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in shares of KemPharm by 0.4% in the first quarter. Geode Capital Management LLC now owns 69,510 shares of the specialty pharmaceutical company’s stock valued at $340,000 after buying an additional 264 shares during the last quarter. Bank of New York Mellon Corp raised its position in KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after buying an additional 3,414 shares in the last quarter. Arete Wealth Advisors LLC raised its position in KemPharm by 0.8% in the third quarter. Arete Wealth Advisors LLC now owns 834,602 shares of the specialty pharmaceutical company’s stock valued at $3,747,000 after buying an additional 6,857 shares in the last quarter. Creative Planning raised its position in KemPharm by 2.3% in the first quarter. Creative Planning now owns 453,723 shares of the specialty pharmaceutical company’s stock valued at $2,223,000 after buying an additional 10,200 shares in the last quarter. Finally, C WorldWide Group Holding A S raised its position in KemPharm by 10.1% in the first quarter. C WorldWide Group Holding A S now owns 181,699 shares of the specialty pharmaceutical company’s stock valued at $890,000 after buying an additional 16,699 shares in the last quarter. Hedge funds and other institutional investors own 44.36% of the company’s stock.

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

5 Day Chart for NASDAQ:KMPH

Receive News & Ratings for KemPharm Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc and related companies with MarketBeat.com's FREE daily email newsletter.